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E-mail address: itohh@ipc.akita-u.ac.jp (H. Itoh).We previously reported that gentamicin (GM) speciﬁcally binds to heat-shock protein with subunit
molecular masses of 70 kDa (HSP70). In the present study, we have investigated the effects of GM
binding on HSP70-assisted protein folding in vitro. The C-terminal, and not the N-terminal of
HSP70 was found to bind to GM. GM signiﬁcantly suppressed refolding of ﬁreﬂy luciferase in the
presence of HSP70 and HSP40, although the ATPase activity of HSP70 was unaffected by GM. A sur-
face plasmon resonance analysis revealed that GM speciﬁcally interferes with the binding of HSP70
to a model peptide that mimics the exposed hydrophobic surface of the folding intermediates. These
results indicated that GM inhibits the chaperone activity of HSP70 and may suppress protein folding
via inhibition of HSP70 in vivo.
Structured summary:
MINT-7384283: HSP40 (uniprotkb:P25685) binds (MI:0407) to HSP70 (uniprotkb:P34930) by surface plas-
mon resonance (MI:0107)
MINT-7384430: RNaseA (uniprotkb:P61823) binds (MI:0407) to HSP70 (uniprotkb:P34930) by surface
plasmon resonance (MI:0107)
Crown Copyright  2009 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction We previously reported that heat-shock protein with subunitAminoglycoside antibiotics are widely used drugs for the treat-
ment of severe Gram-negative bacterial infections, and gentamicin
(GM) is an aminoglycoside antibiotic frequently used for this
purpose. However, aminoglycosides have many nephrotoxic side
effects [1]. GM induces a complex phenomenon characterized by
an increase in the blood urea nitrogen and serum creatinine con-
centration, leading to severe proximal renal tubular necrosis
[2,3]. Thus, its clinical use is often limited by the nephrotoxicity.
Although the role of reactive oxygen metabolites in GM nephropa-
thy has been suggested [4], molecular mechanisms by which GM
disturb renal functions is poorly understood.d by Elsevier B.V. on behalf of Fede
t-shock protein with subunit
rface plasmon resonancemolecular masses of 70 kDa (HSP70), a molecular chaperone re-
quired for protein folding, was induced in injured tubular epithelial
rat kidneys with GM-induced acute renal failure [3]. We also found
that GM co-localizes with HSP70 in the lysosome of GM-treated rat
kidneys in vivo and HSP70 can be puriﬁed from kidney extract
using a GM-afﬁnity column in vitro [5]. Aggregation prevention
activity of HSP70 was suppressed in the presence of GM, and this
drug induced a conformational change in the HSP70. These obser-
vations suggest that GM may inhibit the activities of HSP70 in the
kidney. However, whether GM affect the HSP70-assisted protein
folding is unknown. Moreover, little is known about how GM af-
fects the HSP70 activities by binding.
The HSP70 molecule consists of two domains, i.e., a highly con-
served amino-terminal nucleotide-binding domain (NBD) of
45 kDa and a carboxyl-terminal substrate binding domain (SBD)
of 25 kDa. The SBD is further divided into a b-sandwich subdomain
(b-PDB) and an a-helical subdomain (a-PDB) [6–8]. NBD and SBD
are connected by a ﬂexible linker region that contributes to allostericration of European Biochemical society. All rights reserved.
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similar lobes (I and II), and each of them are further divided into
two small subdomains (IA, IB, IIA and IIB). These subdomains are
separated by a deep cleft that captures ATP and cations (one
Mg2+ and two K+ ions) contacting the four subdomains [6]. The
peptide-binding moiety is composed of two b-sheets with loops
in the b-PDB and two helices (helices A and B) in the a-PDB
[7,11]. Helix B works as the ‘‘lid”, which closes the cavity through
a salt bridge and two hydrogens bound to a loop of b-PDB. The ATP-
bound form of HSP70 rapidly binds and releases a peptide [12,13].
The binding of ATP to the NBD causes a conformational change,
which results in structural alterations in the carboxyl-terminal do-
main leading to substrate release [14,15]. In contrast, the ADP-
bound form of HSP70 slowly binds the peptide but the binding is
more stable. The ATP dependent HSP70 chaperone activity is
tightly regulated by the various co-chaperones including J-domain
proteins (e.g., HSP40) and nucleotide exchange factors [16–19].
In the present study, we investigated how GM affects the HSP70
activities in vitro and found that GM inhibits the HSP70-assisted
protein folding by blocking substrate binding through speciﬁc bind-
ing to the peptide-binding domain. We discuss the role of the GM–
HSP70 interactions during the GM-induced perturbation of cellular
activities including the chaperone-assisted protein folding.2. Materials and methods
2.1. Expression vectors
Human HSP40 (DNAJB1, Accession No. NM_006145) cDNA was
obtained from the Kazusa DNA Research Institute, Japan, and
ampliﬁed by a polymerase chain reaction using oligonucleotides
(50-CTCGAGTATTGGAAGAACCTGCTCAAGTA-30 and 50-CATA-
TGGGTAAAGACTACCAGACG-30) as primers. The ampliﬁed HSP40
cDNA was subcloned into the NdeI–XhoI sites of the pCR2.1 (Life
Technologies Corporation, CA, USA) and pET29a (MERCK, Darms-
tadt, Germany) vectors.
2.2. Protein puriﬁcation
HSP40was expressed inEschericha coliBL21 (DE3) pLysS cells as a
C-terminally 6his-tagged protein. Cells were grown in LBmedium
containingkanamycinandchloramphenicol at 37 C, andexpression
of the 6his-tagged HSP40 was induced with 0.1 mM isopropyl-1-
thio-b-D-galactopyranoside. Cells were resuspended in 10 mM
Tris–HCl (pH 7.4) and lysed by sonication on ice. The supernatant
was recovered after centrifugation at 20 000 rpm for 10 min at
4 C, and applied to a Ni-NTA afﬁnity column (GE Healthcare, Upp-
sala, Sweden) equilibrated with buffer A (0.3 M NaCl and 10 mM
Tris–HCl, pH 7.4) supplementedwith 20 mM imidazole. Afterwash-
ing with 50 mM imidazole in buffer A, proteins were eluted with a
linear gradient of 100–500 mM imidazole in buffer A. The HSP40
peak fractions were pooled and loaded onto a hydroxyapatite HTP
column (Bio-Rad, CA, USA) equilibrated with 100 mM potassium
phosphate buffer (pH 7.0). After washing, the proteins were eluted
with a linear gradient of 100–500 mM potassium phosphate (pH
7.0). After concentration by ultraﬁltration, the HSP40 peak fractions
were applied onto a Superdex 200HR column (GEHealthcare) equil-
ibratedwithbuffer B (5%glycerol, 0.1 MNaCl in25 mMHEPES–KOH,
pH7.4). TheHSP40 fractionswere dialyzed against buffer C (5% glyc-
erol, 1 mMDTT in 25 mMHEPES–KOH, pH 7.4) and stored at80 C.
HSP70 was puriﬁed from porcine brains as follows. The porcine
brains were homogenized in 3 volumes of 1 mM PMSF, 5 mM EDTA,
and 15 mM b-mercaptoethanol in 10 mM Tris–HCl (pH 7.4) on ice
and centrifuged at 13 000 rpm for 30 min at 4 C. The supernatants
were fractionated by ammonium sulfate precipitation and the 45–90% ammonium sulfate fractions were collected. After overnight
dialysis against 10 mM Tris–HCl (pH 7.4), the proteins were applied
onto a Q-sepharose column (GE Healthcare) equilibrated with
10 mM Tris–HCl (pH 7.4). After washing with 0.1 M NaCl in
10 mM Tris–HCl (pH 7.4), the proteins were eluted with 0.3 M NaCl
in 10 mM Tris–HCl (pH 7.4). After the addition of 50 mM KCl and
5 mM MgCl2 (ﬁnal concentrations), the HSP70 peak fractions were
load onto an ATP-sepharose column (Sigma, St. Louis, MO, USA)
equilibrated with buffer D (0.3 M NaCl, 5 mM MgCl2, 50 mM KCl
and 10 mM Tris–HCl, pH 7.4). After washing in buffer D, the column
was further washed in buffer E (5 mM MgCl2, 50 mM KCl and
100 mM Tris–HCl, pH 7.4). The proteins were eluted with a linear
gradient of 0–20 mMATP in buffer E. After concentration by ultraﬁl-
tration, the HSP70 peak fractions were separated on a Superdex 200
column (GE Healthcare) equilibrated with buffer B. The HSP70 frac-
tions were dialyzed against buffer C and stored at 80 C.
The amino-terminal and carboxyl-terminal domains of HSP70
(HSP70N and HSP70C, respectively) were puriﬁed as previously de-
scribed [20].
2.3. GM-afﬁnity column chromatography
GM-Sepharose was prepared using GM (Sigma) and CH-acti-
vated Sepharose 4B (GE Healthcare) according to the manufac-
turer’s instructions. The 6his-tagged HSP70N or HSP70C was
applied to a GM-Sepharose column equilibrated with 10 mM
Tris–HCl (pH 7.4) and washed with 3 column volumes of 0.15 M
NaCl in 10 mM Tris–HCl (pH 7.4). The proteins were eluted with
5 mM GM, 0.15 M NaCl in 10 mM Tris–HCl (pH 7.4) and analyzed
on SDS/PAGE (9% gel) followed by silver staining.
2.4. Surface plasmon resonance (SPR) assay
2.4.1. Measurement of HSP40 and HSP70 interaction
All SPR measurements using a performed on a BIAcore 2000
instrument (GE Healthcare) at 25 C, and 25 mM HEPES–KOH (pH
7.4) buffer containing 0.005% Tween 20, 5 mM MgCl2, and
150 mM KCl was used as the running buffer at the ﬂow rate of
10 ll/ min. His-HSP40 (0.1 lM) dissolved in 10 mM potassium
phosphate buffer (pH 7.0) was immobilized on CM5 sensor chips
(GE Healthcare) through the amine coupling reaction, which was
performed according to the standard procedure. HSP40 (4000
RU) was immobilized on the chip by this procedure, and 40 ll of
HSP70 solutions (31.3–4000 nM) with or without 10 mM GM was
loaded on the chip using running buffer supplemented with
1 mM ATP. Regeneration of the sensor chip surface was achieved
by three 1-min pulses of 1 M urea in the running buffer (10 ll).
The dissociation constant (KD) and observed reaction rate constant
(Kobs) were obtained by non-linear curve ﬁtting based on a 1:1
binding with a drifting baseline using BIAevaluation 3.0 software.
2.4.2. Measurement of HSP70 interaction with immobilized peptide
An HSP70-binding model peptide (CKETAAAKFERQHMDSSTS),
which consists of the amino-terminal 1–18 residues of RNase A
[21,22] and an additional cysteine for immobilization on the sensor
chip, was purchased from Biosynthesis, USA. Ethylenediamine was
coupled on the surface of the C1 sensor chip (GEHealthcare) by sub-
sequent injection of a 0.1 M 1-ethyl-3-(3-dimethylaminopro-
pyl)carbodiimide/0.05 M N-hydroxysuccinimide solution and
0.1 M ethylenediamine (70 ll each). Carboxyl groups on the sensor
surface were blocked with 1 M monoethanolamine, and NHS-
PEG6-maleimide (Pierce, Rockford, USA), a spacer for coupling with
the cysteine residue, was introduced using a 5 mM solution. After
the model peptide (1 mM) was injected using the running buffer,
the free maleimide residues are blocked with 1 M L-cysteine. The
peptides immobilized on the surface of the sensor chip were 210
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0–10 mMGMwere loaded onto the sensor chip. Regeneration of the
sensor chip surface was achieved by a 30-s pulse (5 ll) of 10 mM
NaOH and a 1-min pulse (10 ll) of 0.5 M NaCl in running buffer.
2.4.3. Measurement of GM interaction to HSP70
Porcine brain HSP70 (1 lM) was dissolved in 100 mM sodium
acetate buffer (pH 4.0) and immobilized on CM5 sensor chips (GE
Healthcare) by amino coupling. HSP70 (15 000 RU) was immobi-
lized on the chip, and GM solutions (19.5 lM to 20 mM) were
loaded on the chip using running buffer. Regeneration of the sensor
chip surface was achieved by 1-min pulse (10 ll) of 0.5 M NaCl in
running buffer. The dissociation constant (KD) was obtained by
non-linear curve ﬁtting based on a steady-state afﬁnity using BIA-
evaluation 3.0 software.
2.5. Measurement of protein aggregation
Thermal aggregation of recombinant ﬁreﬂy luciferase (0.15 lM)
(Promega) in 25 mM HEPES–KOH (pH 7.4) at 42 C was monitored
by optical density at 360 nm using a Pharmacia Ultrospec 3000
UV–Vis spectrophotometer equipped with a semi-micro-cuvette
(0.5 ml) with a path length of 10 nm and a temperature control unit.
In this experiment, the absorbance of 0.05was observed bymaximal
aggregation and used as the value for 100% aggregation. In the
presence of porcine HSP70 (0.3 lM) and various concentrations of
GM, aggregation of ﬁreﬂy luciferase was analyzed after incubation
of 2 min, and 50% inhibitory concentration (IC50) was calculated
using origine 6.1 software (Origine Laboratory, Northampton, USA).
2.6. Luciferase refolding assay
Recombinant ﬁreﬂy luciferase (6.25 lM) (Promega, Madison,
USA) was incubated for 30 min at 30 C in denaturing buffer (6 M
guanidine–HCl, 5 mM MgCl2, and 50 mM KCl in 25 mM HEPES–
KOH, pH 7.4). For refolding, the denatured luciferase was diluted
125-fold into renaturation buffer (2 mM DTT, 2 mM ATP, 5 mM
MgCl2, and 50 mM KCl in 25 mM HEPES–KOH, pH 7.4) in the pres-
ence of 1 lM HSP40 and 2 lM HSP70. The refolding reaction mix-
ture was incubated at 30 C up to 70 min in the presence or
absence of GM. At each sampling time point, aliquots (1 ll) were
mixed with 1 mg/ml BSA/25 mM HEPES–KOH, pH 7.4 (19 ll) and
the luciferase activity was determined using luciferase assay re-
agent (Promega) and Inﬁnite M200 (TECAN, Mannedorf, Switzer-
land). The refolding activity was evaluated by the percent
luciferase activity versus the native enzyme.
2.7. Measurement of ATPase activity
HSP70 (0.5 lM) was incubated with 0.5 mM ATP in a buffer
containing 1 mM DTT, 5 mM MgCl2, 50 mM KCl and 25 mM
HEPES–KOH (pH 7.4) at 37 C up to 120 min. After incubation,
the samples (50 ll) were transferred to a 96-well plate and BIO-
MOL GREEN reagent (100 ll) (Enzo Life Science, New York, USA)
was added. After the samples were incubated for 30 min at room
temperature, the absorbance at 650 nm was determined. The free
phosphate concentrations were estimated using an experimentally
determined standard curve.3. Results
3.1. GM-binding domain of HSP70
The GM-binding assay of the HSP70 fragments prepared by par-
tial digestion with TPCK-trypsin suggested that the GM-bindingdomain of HSP70 may localize in a carboxyl-terminal region [5].
To exactly determine the GM-binding domain, the 45 kDa HSP70N
and 35 kDa HSP70C domains were expressed in E. coli and puriﬁed
from the bacteria. These recombinant proteins were applied onto a
GM-afﬁnity column and eluted with 5 mM GM. The SDS–PAGE
analysis of the eluates indicated that HSP70C strongly binds to
the GM-afﬁnity column (Fig. 1B). In contrast, HSP70N exhibited
no signiﬁcant binding to the column (Fig. 1A). These results clearly
indicated that the GM-binding site of HSP70 is located in the
35 kDa carboxyl-terminal region, which contains the SBD domain
of 25 kDa for the substrate peptide recognition [23]. Furthermore,
we determined the dissociation constant (KD) between HSP70 and
GM by SPR experiments. HSP70 puriﬁed from porcine brain was
immobilized on the surface of a sensor chip, and various concen-
trations of GM were injected (Fig. 1C). A plot of GM concentrations
versus equilibration value (Req) (Fig. 1D) provided a KD value of
3.64 ± 0.22  103 M.
3.2. GM inhibits HSP70-assisted protein folding
We previously indicated that GM diminishes the aggregation
prevention activity of HSP70 using rhodanase as a substrate [5].
To examine whether GM affects the protein folding by HSP70, we
analyzed the refolding of ﬁreﬂy luciferase as a model substrate.
Luciferase was denatured using 6 M guanidine–HCl, and refolding
was initiated by dilution in renaturation buffer containing HSP70
puriﬁed from the porcine brain. The spontaneous refolding was
5.4 ± 2.3% and the refolding rate in the presence of HSP70 was
5.4 ± 1.4% after incubation for 70 min (Fig. 2A), indicating that
HSP70 alone has no effect on the luciferase refolding. Although
the refolding rate slightly increased to 12.4 ± 1.9% in the presence
of HSP40, it was signiﬁcantly increased to 44.8 ± 5.2% in the simul-
taneous presence of HSP70 and HSP40. These results indicate that
HSP70 and HSP40 are both required for the luciferase refolding be-
cause they work as a chaperone system, in good agreement with
previous reports [24]. In the presence of HSP70 and HSP40, the
refolding of luciferase was strongly suppressed by GM in a concen-
tration-dependent manner; 25.8 ± 3.8% and 10.5 ± 1.4% in the pres-
ence of 5 mM and 10 mM GM, respectively (Fig. 2B). In contrast,
the inhibitory effect by GM on the luciferase refolding was very
low in the presence of HSP40 alone; the refolding rate was
9.8 ± 1.8% and 5.0 ± 1.0% in the presence of 5 mM and 10 mM
GM, respectively (Fig. 2C). In addition, GM at 10 mM had no effect
on the enzymatic activity of the native luciferase (data not shown).
These results indicate that GM inhibited protein refolding assisted
by the HSP40–HSP70 chaperone system, probably by direct bind-
ing to the HSP70C domain.
We also analyzed the ATPase activity of HSP70 in the presence
of GM, because the binding of substrates to HSP70 is known to
stimulate the ATPase activity [23,25]. However, the ATPase activity
of HSP70 was unaffected in the presence of GM. Thus, although this
drug binds to the substrate binding domain of HSP70, this binding
does not affect the activity of the ATPase domain (Fig. 3). The GM
and substrate polypeptides may differ in their ability to induce a
conformational change in HSP70. Taken together, these observa-
tions suggest substrate recognition, but not the ATPase activity,
of HSP70 is affected by the GM binding to a carboxyl-terminal
region.
3.3. GM inhibits HSP70–substrate peptide interaction, but not HSP70–
HSP40 interaction
GM inhibited the refolding of luciferase by the HSP40–HSP70
chaperone system (Fig. 2B), and there were two possibilities
explaining this result; GM inhibited the HSP70–substrate interac-
tion or HSP70–HSP40 interaction. We ﬁrst tested whether GM af-
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648 S. Yamamoto et al. / FEBS Letters 584 (2010) 645–651fects HSP70–substate interaction by measuring aggregation pre-
vention activity of HSP70 using luciferase as a substrate. Luciferase
was aggregated at 42 C, but the aggregation was completely
inhibited by the presence of HSP70 (Fig. 4A). Aggregation preven-
tion activity of HSP70 was diminished by GM in a concentration-
dependent manner (Fig. 4B), and IC50 of the GM activity was calcu-
lated to be 140 ± 7 lM (Fig. 4C). These results strongly suggested
that GM speciﬁcally inhibited substrate recognition of HSP70.
Next, we examined the effects of GM on the HSP70 binding to
the substrate by SPR using a model peptide containing the ami-no-terminal 1–18 residues of RNase A, because this peptide is
known to bind to HSP70 [21,25]. This model peptide was ﬁrst
immobilized on the surface of a sensor chip, then HSP70 solutions
containing 0–10 mM GM were injected. A sensorgram for the
HSP70-model peptide system in the absence of GM is shown in
Fig. 5A, which gives a KD of 2.26  108 M. The KD value represents
a strong interaction between HSP70 and the model peptide. In the
presence of GM, the SPR signals signiﬁcantly decreased with the
change in the GM concentration. This result indicates that GM
blocks the binding of HSP70 to the immobilized model peptide.
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interaction using an HSP40-immobilized chip. Since the HSP40–
HSP70 interaction is known to be ATP dependent [28], an SPR assay
was performed in the presence and absence of ATP. No signiﬁcant
HSP40–HSP70 interaction was detected in the absence of the ATP,
regardless of the GM addition (Fig. 5B and unpublished data). In
the presence of ATP, HSP70 signiﬁcantly interacted with HSP40
in the absence of GM and KD was estimated to be
2.13 ± 0.24  106 M. In the presence of 10 mM GM, the KD was
2.79 ± 0.84  106, indicating that GM has a slight or no effect on
the HSP40–HSP70 interaction (Fig. 5B and C, Supplementary
Fig. 1 and Table 1). Taken together, these observations indicate that
GM inhibits the chaperone activity of HSP70 by interfering with
the substrate recognition.
4. Discussion
In the present study, we demonstrated that GM strongly sup-
presses protein folding by the HSP40–HSP70 chaperone system
without affecting the ATPase activity (Figs. 2 and 3). Moreover,
GM signiﬁcantly inhibited the aggregation prevention activity of
HSP70 (IC50 = 140 ± 7 lM), although the effect on the HSP40–
HSP70 interaction was very low (Figs. 4 and 5). These observations
indicate that GM signiﬁcantly inhibits the protein folding activity
of HSP70 by modulating substrate recognition.
We also found that GM binds to the carboxyl-terminal peptide-
binding domain, but not to the amino-terminal nucleotide-binding
domain of HSP70 (Fig. 1A and B). GM inhibited binding of HSP70 to
a model peptide (Fig. 5A). These results suggest that GM has an
inhibitory effect on peptide recognition by the carboxyl-terminal
peptide-binding domain. However, KD value of HSP70–GM interac-
tion was estimated to be 3.6  103 M (Fig. 1C and D), indicating a
weak or transient interaction. Since IC50 for the inhibition of
HSP70-dependent aggregation prevention was signiﬁcantly lower
than the KD value, the weak or transient interaction may induce
structural alteration of HSP70 rather than direct competition to
substrate peptides. It may also be possible that GM interferes
HSP70–substrate binding by interacting with HSP70 and substrate
proteins.
The peptide-binding domain in the carboxyl-terminal region of
HSP70 is known to recognize the hydrophobic core of folding inter-
mediates or the unstructured backbone of the non-native protein
[26,27]. These interactions stimulate productive folding of newly-
synthesized polypeptides or refolding of denatured proteins by
preventing any non-essential interaction of hydrophobic cores in
a protein and aggregation of partially folded proteins. In our previ-ously study, binding of GM to HSP70 resulted in a conformational
change of HSP70 [5]. However, the ATPase activity of HSP70, which
is known to be stimulated by the presence of the substrate protein,
was unaffected by GM. Thus, the conformational change may be
limited in the carboxyl-terminal region and the effect of the con-
formational change may not be transferred to the amino-terminal
region.
Although a number of inhibitors have been reported for HSP90,
including geldanamycin derivatives, novobiocin and cisplatin
[29–31], there are only a few inhibitors of HSP70. We previously
reported that geranly-geranyl-acetone (GGA) inhibits the aggregation
prevention activity of HSP70 by binding to the carboxyl-terminal
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Fig. 5. GM signiﬁcantly inhibits HSP70–peptide interaction but not HSP70–HSP40
interaction as analyzed by SPR. (A) A sensorgram of HSP70 interaction with model
peptide in the presence of GM. HSP70 solutions containing different concentrations
of GM were loaded onto peptide-immobilized sensor chip. (B) Sensorgrams of
HSP70 interacting with HSP40 in the presence or absence of ATP and GM. The
HSP70 concentration was ﬁxed at 1 lM. (C) A plot of observed reaction rate
constant (Kobs) versus HSP70 concentration. Open circle and closed square indicate
the presence and absence of GM, respectively. Mean and S.D. at least three
independent measurements are shown.
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aminomethylbenzoyl)]-L-asparagine, a fatty acylated benzamido
derivative, prevents bacteria growth by inhibiting the protein fold-
ing activity of the bacterial homologue of HSP70, DnaK [32]. As this
substance competed with the substrate peptides for the DnaK
binding, its binding site appears to be the substrate recognition do-
main at the carboxyl-terminus. An hydrophobic interaction is
probably important to the binding of GGA and the fatty acylated
benzamido derivative to HSP70/DnaK, because these substances
have a hydrophobic straight carbon chain and the inhibitory effectof the latter is increased with extension of the carbon chain. In con-
trast, GM has no hydrophobic straight carbon chain. Thus, GM may
differ from the other two substances in the mode of interaction
with HSP70 at least in part, although these three substances block
binding of the substrate proteins to the carboxyl-terminal region of
HSP70/DnaK.
GM is administered at 4–5 mg/kg every 36–48 h on clinical use
(extended interval method), because concentration of GM in blood
decreases 2.5 mg/kg every 12 h. The peak concentration and trough
concentration of GM in blood using the extended interval method
are 5–12 lg/ml (approx. 11–26 lM) and under 2 lg/ml (approx.
4 lM), respectively [33]. Most of administered GM (approx.
70–90%) is excretes into urine, and speciﬁcally accumulates in
the cortex of kidney via megalin receptor within 30 min after GM
administration. The accumulated GM persists in the kidney for a
long time (half-life > 100 h) [34,35]. GM is highly accumulated in
lysosomes (approx. 90%), providing a very high concentration
(30 mM or more) [36]. Approximately 10% of GM localizes with
cytoplasm, nuclear, mitochondria and endoplasmic reticulum
[37]. Concentration of GM to lysosome is thought to cause destruc-
tion of this organelle [34,38,39], and it probably increases GM con-
centration in the cytosol. Thus, the GM concentration in the cytosol
of kidney cells in patients can be comparable to the GM concentra-
tion to inhibit 50% of HSP70-dependent aggregation prevention
activity (140 lM).
The HSP70 family chaperones are highly conserved proteins
that play essential roles in the protein metabolism and quality con-
trol by controlling the protein folding, translocation, degradation
and gene expression [26,40]. Thus, inhibition of the HSP70 activi-
ties, including folding of the newly-synthesized proteins and
refolding of misfolded proteins by GM may result in perturbation
of the cellular activities essential for cell survival. Since GM co-
localizes with HSP70 in the enlarged lysosomes of the rat kidneys
with GM-induced acute tubular injury in vivo [5], GM may affect
the HSP70 activity required for kidney cells and cause nephrotox-
icity via the HSP70 inhibition.
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